• LAST PRICE
    2.6600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.6600/ 10
  • Ask / Lots
    2.9500/ 7
  • Open / Previous Close
    0.0000 / 2.6600
  • Day Range
    ---
  • 52 Week Range
    Low 1.5700
    High 34.3300
  • Volume
    5
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeENVB
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesENVB
Enveric Biosciences Inc
5.5M
0.0x
---
United StatesBIEI
Premier Biomedical Inc
5.5M
-0.3x
---
United StatesCAPS
Capstone Holding Corp
5.8M
-5.6x
---
United StatesRCAR
RenovaCare Inc
5.2M
-0.9x
---
United StatesFWBI
First Wave BioPharma Inc
5.8M
0.0x
---
United StatesVIRI
Virios Therapeutics Inc
5.9M
-0.2x
---
As of 2023-01-31

Company Information

Enveric Biosciences, Inc. is an early-development-stage biosciences company. The Company is developing next-generation mental health and oncology treatments using a clinical discovery platform to enable psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. It is developing its product candidates that are focused on cannabinoids derived from non-hemp botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) in order to comply with United States federal regulations. Its product candidates include EV104, EVM-101, EVM-201, EVM-301, EV102 and EV101. EV104 includes cannabidiol (CBD) and celecoxib conjugate. EVM-101 is a first-generation psychedelic asset, which is a psilocybin oral formulation. EVM-201 is a second-generation psychedelic asset, which is a prodrug of psilocin. EVM-301 is a third-generation psychedelic. EV102 is a cannabinoid cream for topical skin application. EV101 is a cannabinoid plus chemotherapy combination therapy.

Contact Information

Headquarters
4851 Tamiami Trail N, Suite 200NAPLES, FL, United States 34103
Phone
239-302-1707
Fax
732-243-9254

Executives

Executive Chairman of the Board
David Johnson
President, Chief Operating Officer
Avani Kanubaddi
Chief Executive Officer, Director
Joseph Tucker
Interim Chief Financial Officer
Robert Dickey
Chief Medical Officer
Bob Dagher

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.5M
Revenue (TTM)
$0.00
Shares Outstanding
2.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.44
EPS
$-72.38
Book Value
$34.23
P/E Ratio
0.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.